All In Biotech

Drug Trial Radar · NCT07874269

MSC Secretome and rTMS for Motor Recovery After Subacute Ischemic Stroke

Effectiveness of Combined Mesenchymal Stem Cell Secretome and Repetitive Transcranial Magnetic Stimulation on Motor Recovery and Quantitative Electroencephalography Biomarkers in Patients With Subacute Ischemic Stroke: A Double-Blind Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 205 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

205

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jul 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Jumraini TammasseAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 30 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, controlled clinical trial evaluates the effectiveness and safety of combined mesenchymal stem cell (MSC) secretome and repetitive transcranial magnetic stimulation (rTMS) for motor recovery in patients with subacute ischemic stroke. Participants will be randomized to either an intervention group receiving intravenous MSC secretome combined with high-frequency ipsilesional rTMS or a control group receiving placebo infusion and sham rTMS. The intervention is administered once weekly for 8 weeks. The primary outcome is change in motor function measured using the Fugl-Meyer Motor Scale. Secondary outcomes include changes in quantitative electroencephalography biomarkers, including sensorimotor rhythm, delta-theta-to-alpha-beta ratio, and beta coherence, as well as spasticity assessed using the Modified Ashworth Scale and treatment-related adverse events.

Conditions

  • Ischemic Stroke

Interventions

  • Mesenchymal Stem Cell-Derived SecretomeBiological

    Intravenous mesenchymal stem cell-derived secretome at a dose of 1.5 × 10\^9 particle equivalents is administered once weekly for 8 weeks. Administration is performed through intravenous access using aseptic technique by trained medical personnel, with monitoring for possible adverse events during and after administration.

  • Active Repetitive Transcranial Magnetic StimulationDevice

    High-frequency repetitive transcranial magnetic stimulation is delivered at 10 Hz, 1500 pulses per session, at 80% of the resting motor threshold over the ipsilesional primary motor cortex (M1). Treatment is administered once weekly for 8 weeks.

  • 0.9% Sodium Chloride PlaceboDrug

    Participants in the control group receive an intravenous infusion of 0.9% sodium chloride as placebo according to the same treatment schedule as the active secretome intervention.

  • Sham Repetitive Transcranial Magnetic StimulationDevice

    Sham repetitive transcranial magnetic stimulation is performed using procedures designed to resemble active rTMS without delivering therapeutic stimulation. Sham sessions follow the same treatment schedule as the active rTMS sessions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Fugl-Meyer Motor Scale ScoreTime frame: Baseline to week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Inggit Medical Centre

    Makassar, South Sulawesi, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.